FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neurofibromatosis type 1 (NF1) is a common neurocutaneous disorder.
• Malignant peripheral nerve sheath tumors (MPNST) develop in approximately 25% of NF1 patients.
• FT895, an HDAC11 inhibitor, shows anti-tumor activity against MPNST.

Purpose of the Study:

• To investigate the molecular mechanisms of FT895 efficacy in MPNST cells.
• To elucidate how FT895 impacts mitochondrial function and biogenesis in MPNST.

Main Methods:

• Mitochondrial DNA copy number analysis.
• Seahorse XF analysis for cellular respiration.
• Immunostaining for mitochondrial proteins.
• CHIP-qPCR to assess gene promoter copy numbers.
• RNA-sequencing (RNA-seq) to analyze signaling pathways.

Main Results:

• FT895 treatment increased reactive oxygen species (ROS) and decreased mitochondrial DNA copy numbers.
• Basal, maximal, and ATP-coupled respiration were significantly reduced post-FT895 treatment.
• FT895 promoted mitochondrial aggregation without mitophagy, linked to reduced XBP1, Parkin, and PINK1.
• CHIP-qPCR showed reduced copy numbers for key mitochondrial gene promoters.
• RNA-seq identified the HIF-1α signaling pathway as significantly upregulated, correlating with impaired mitochondrial respiration.

Conclusions:

• FT895 induces mitochondrial respiratory damage in MPNST cells.
• The findings suggest FT895's potential as a therapeutic agent for MPNST by targeting mitochondrial dysfunction.